title: Transmission of meropenem in breast milk.
abstract: A case is presented of a breast-feeding mother receiving meropenem treatment for a postpartum urinary tract infection caused by extended-spectrum beta-lactamase producing Escherichia coli. Five milk samples were collected in a 48-hour period during meropenem therapy. The average and maximum meropenem concentrations in milk were 0.48 and 0.64 µg/mL, respectively. Based on the maximum concentration, the calculated infant daily exposure from breast milk was 97 µg/kg/d, and the infant weight-adjusted percentage of maternal dosage was 0.18%. There were no dermatologic or gastrointestinal side effects noted in the breastfed infant. Meropenem appears to be acceptable to use during breast-feeding.
authors.affiliation: Department of Pharmacy, University of California, San Diego Medical Center and UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA. jsauberan@ucsd.edu
authors.forename: Jason B
authors.initials: JB
authors.lastname: Sauberan
authors.forename: John S
authors.initials: JS
authors.lastname: Bradley
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Blumer
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Stellwagen
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000032:analysis / Q000493:pharmacokinetics*; D001942:Breast Feeding; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007774:Lactation / Q000378:metabolism*; D000077731:Meropenem; D008895:Milk, Human / Q000737:chemistry*; D011247:Pregnancy; D013845:Thienamycins / Q000008:administration & dosage / Q000009:adverse effects / Q000032:analysis / Q000493:pharmacokinetics*; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000077731:Meropenem